Cargando…

Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons

Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD(+) levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD(+)) levels to prevent dementia. We tested if the administration of the precursor of NAD(+), ni...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Krish, Choi, Joungil, Arvas, Muhammed Ikbal, Salimian, Mohammad, Singh, Sujal, Xu, Su, Gullapalli, Rao P, Kristian, Tibor, Russell, James William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313029/
https://www.ncbi.nlm.nih.gov/pubmed/32466541
http://dx.doi.org/10.3390/ijms21113756
_version_ 1783549864435515392
author Chandrasekaran, Krish
Choi, Joungil
Arvas, Muhammed Ikbal
Salimian, Mohammad
Singh, Sujal
Xu, Su
Gullapalli, Rao P
Kristian, Tibor
Russell, James William
author_facet Chandrasekaran, Krish
Choi, Joungil
Arvas, Muhammed Ikbal
Salimian, Mohammad
Singh, Sujal
Xu, Su
Gullapalli, Rao P
Kristian, Tibor
Russell, James William
author_sort Chandrasekaran, Krish
collection PubMed
description Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD(+) levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD(+)) levels to prevent dementia. We tested if the administration of the precursor of NAD(+), nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD(+) levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD(+) levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD(+), activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats.
format Online
Article
Text
id pubmed-7313029
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73130292020-06-29 Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons Chandrasekaran, Krish Choi, Joungil Arvas, Muhammed Ikbal Salimian, Mohammad Singh, Sujal Xu, Su Gullapalli, Rao P Kristian, Tibor Russell, James William Int J Mol Sci Article Diabetes predisposes to cognitive decline leading to dementia and is associated with decreased brain NAD(+) levels. This has triggered an intense interest in boosting nicotinamide adenine dinucleotide (NAD(+)) levels to prevent dementia. We tested if the administration of the precursor of NAD(+), nicotinamide mononucleotide (NMN), can prevent diabetes-induced memory deficits. Diabetes was induced in Sprague-Dawley rats by the administration of streptozotocin (STZ). After 3 months of diabetes, hippocampal NAD(+) levels were decreased (p = 0.011). In vivo localized high-resolution proton magnetic resonance spectroscopy (MRS) of the hippocampus showed an increase in the levels of glucose (p < 0.001), glutamate (p < 0.001), gamma aminobutyric acid (p = 0.018), myo-inositol (p = 0.018), and taurine (p < 0.001) and decreased levels of N-acetyl aspartate (p = 0.002) and glutathione (p < 0.001). There was a significant decrease in hippocampal CA1 neuronal volume (p < 0.001) and neuronal number (p < 0.001) in the Diabetic rats. Diabetic rats showed hippocampal related memory deficits. Intraperitoneal NMN (100 mg/kg) was given after induction and confirmation of diabetes and was provided on alternate days for 3 months. NMN increased brain NAD(+) levels, normalized the levels of glutamate, taurine, N-acetyl aspartate (NAA), and glutathione. NMN-treatment prevented the loss of CA1 neurons and rescued the memory deficits despite having no significant effect on hyperglycemic or lipidemic control. In hippocampal protein extracts from Diabetic rats, SIRT1 and PGC-1α protein levels were decreased, and acetylation of proteins increased. NMN treatment prevented the diabetes-induced decrease in both SIRT1 and PGC-1α and promoted deacetylation of proteins. Our results indicate that NMN increased brain NAD(+), activated the SIRT1 pathway, preserved mitochondrial oxidative phosphorylation (OXPHOS) function, prevented neuronal loss, and preserved cognition in Diabetic rats. MDPI 2020-05-26 /pmc/articles/PMC7313029/ /pubmed/32466541 http://dx.doi.org/10.3390/ijms21113756 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chandrasekaran, Krish
Choi, Joungil
Arvas, Muhammed Ikbal
Salimian, Mohammad
Singh, Sujal
Xu, Su
Gullapalli, Rao P
Kristian, Tibor
Russell, James William
Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
title Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
title_full Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
title_fullStr Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
title_full_unstemmed Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
title_short Nicotinamide Mononucleotide Administration Prevents Experimental Diabetes-Induced Cognitive Impairment and Loss of Hippocampal Neurons
title_sort nicotinamide mononucleotide administration prevents experimental diabetes-induced cognitive impairment and loss of hippocampal neurons
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313029/
https://www.ncbi.nlm.nih.gov/pubmed/32466541
http://dx.doi.org/10.3390/ijms21113756
work_keys_str_mv AT chandrasekarankrish nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT choijoungil nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT arvasmuhammedikbal nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT salimianmohammad nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT singhsujal nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT xusu nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT gullapalliraop nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT kristiantibor nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons
AT russelljameswilliam nicotinamidemononucleotideadministrationpreventsexperimentaldiabetesinducedcognitiveimpairmentandlossofhippocampalneurons